Fleury Group to License IDbyDNA NGS Platform

Sep 19, 2018

|

The story has been amended to update the number of bacterial, fungal, and viral respiratory pathogens detected by IDbyDNA's technology.

NEW YORK (GenomeWeb) – IDbyDNA announced today that it has signed a licensing agreement with Brazil-based Fleury Group to offer IDbyDNA's Explify platform for clinical metagenomic testing in South America.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Fleury Group to License IDbyDNA NGS Platform

To read the full story....

Breaking News

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

What's Popular?

Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Cellex, Gauss Partner on At-Home, Point-of-Care Coronavirus Antigen Test

Novacyt H1 Revenues Surge on Coronavirus Testing Product Sales

Sponsorships